(VIANEWS) – Alexandria Real Estate Equities (ARE), Nu Skin Enterprises (NUS), Ames National Corporation (ATLO) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio up to now. The payout ratio in itself isn’t a guarantee of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. Alexandria Real Estate Equities (ARE)
142.77% Payout Ratio
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche since its founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative life science, agtech, and advanced technology campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The trusted partner to approximately 825 tenants, Alexandria has a total market capitalization of $30.6 billion and an asset base in North America of 74.9 million SF as of June 30, 2023, which includes 41.1 million RSF of operating properties and 5.3 million RSF of Class A/A+ properties undergoing construction, 9.4 million RSF of near-term and intermediate-term development and redevelopment projects, and 19.1 million SF of future development projects. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in life science, agtech, and advanced technology campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science, agrifoodtech, climate innovation, and technology companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.
Earnings Per Share
As for profitability, Alexandria Real Estate Equities has a trailing twelve months EPS of $3.39.
PE Ratio
Alexandria Real Estate Equities has a trailing twelve months price to earnings ratio of 35.94. Meaning, the purchaser of the share is investing $35.94 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.4%.
Volume
Today’s last reported volume for Alexandria Real Estate Equities is 100120 which is 90.19% below its average volume of 1020710.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 28, 2023, the estimated forward annual dividend rate is 4.96 and the estimated forward annual dividend yield is 4.31%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Alexandria Real Estate Equities’s EBITDA is 11.2.
2. Nu Skin Enterprises (NUS)
110.71% Payout Ratio
Nu Skin Enterprises, Inc., together with its subsidiaries, develops and distributes various beauty and wellness products worldwide. It offers skin care devices, cosmetics, and other personal care products, including ageLOC LumiSpa and ageLOC LumiSpa iO, ageLOC Body Spa; and nutricentials skin care products. The company also provides wellness products, such as ageLOC Meta, LifePak nutritional supplements, ageLOC TR90 weight management system, and Beauty Focus Collagen+. In addition, it is involved in the research and product development of skin care products and nutritional supplements. The company sells its products under the Nu Skin, Pharmanex, and ageLOC brands through retail stores, website, digital platforms, and independent direct sellers and marketers, as well as a service center. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.
Earnings Per Share
As for profitability, Nu Skin Enterprises has a trailing twelve months EPS of $1.54.
PE Ratio
Nu Skin Enterprises has a trailing twelve months price to earnings ratio of 15.81. Meaning, the purchaser of the share is investing $15.81 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.63%.
Volume
Today’s last reported volume for Nu Skin Enterprises is 481353 which is 40.98% below its average volume of 815587.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Aug 23, 2023, the estimated forward annual dividend rate is 1.56 and the estimated forward annual dividend yield is 6.45%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Nu Skin Enterprises’s EBITDA is 0.76.
Moving Average
Nu Skin Enterprises’s worth is way under its 50-day moving average of $29.89 and way under its 200-day moving average of $37.40.
3. Ames National Corporation (ATLO)
61.71% Payout Ratio
Ames National Corporation operates as a multi-bank holding company that provides banking products and services primarily in Boone, Clarke, Hancock, Marshall, Polk, Story, and Union counties in central, north-central, and south-central Iowa. The company accepts a range of deposits, including checking and savings accounts; and time deposits, such as money market accounts and certificates of deposit. It also provides loans, such as short-term and medium-term commercial and agricultural real estate, residential real estate loans, equipment, vehicle, and home improvement loans; personal loans and lines of credit; agricultural and business operating loans and lines of credit; and originates mortgage loans for sale into the secondary market. In addition, the company offers cash management, merchant credit card processing, safe deposit box, wire transfer, direct deposit of payroll and social security check, and automated/video teller machine access services; and automatic drafts for various accounts, as well as wealth management services. Further, it provides farm management, investment, and custodial services for individuals, businesses, and non-profit organizations; and online, mobile, and private banking services. Ames National Corporation was founded in 1903 and is based in Ames, Iowa.
Earnings Per Share
As for profitability, Ames National Corporation has a trailing twelve months EPS of $1.75.
PE Ratio
Ames National Corporation has a trailing twelve months price to earnings ratio of 10.41. Meaning, the purchaser of the share is investing $10.41 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.05%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 15.5%, now sitting on 58.38M for the twelve trailing months.
Yearly Top and Bottom Value
Ames National Corporation’s stock is valued at $18.22 at 14:23 EST, way below its 52-week high of $25.00 and above its 52-week low of $17.51.
Moving Average
Ames National Corporation’s worth is below its 50-day moving average of $18.83 and way below its 200-day moving average of $21.10.
4. Bristol (BMY)
59.84% Payout Ratio
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Bristol has a trailing twelve months EPS of $3.43.
PE Ratio
Bristol has a trailing twelve months price to earnings ratio of 17.84. Meaning, the purchaser of the share is investing $17.84 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.66%.
Moving Average
Bristol’s value is under its 50-day moving average of $63.06 and way below its 200-day moving average of $69.44.
Previous days news about Bristol (BMY)
- According to Zacks on Monday, 21 August, "Cabozantinib tablets are approved in the United States under the brand name Cabometyx for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) who have been previously treated with sorafenib and for patients with advanced RCC as a first-line treatment in combination with Bristol Myers’ (BMY Quick QuoteBMY – Free Report) Opdivo."
5. Provident Financial Services (PFS)
43.44% Payout Ratio
Provident Financial Services, Inc. operates as the bank holding company for Provident Bank that provides various banking products and services to individuals, families, and businesses in the United States. Its deposit products include savings, checking, interest-bearing checking, money market deposit, and certificate of deposit accounts, as well as IRA products. The company's loan portfolio comprises commercial real estate loans that are secured by properties, such as multi-family apartment buildings, office buildings, and retail and industrial properties; commercial business loans; fixed-rate and adjustable-rate mortgage loans collateralized by one- to four-family residential real estate properties; commercial construction loans; and consumer loans consisting of home equity loans, home equity lines of credit, marine loans, personal loans and unsecured lines of credit, and auto and recreational vehicle loans. It also offers cash management, remote deposit capture, payroll origination, escrow account management, and online and mobile banking services; and business credit cards. In addition, the company provides wealth management services comprising investment management, trust and estate administration, financial planning, tax compliance and planning, and private banking. Further, it sells insurance and investment products, including annuities; operates as a real estate investment trust for acquiring mortgage loans and other real estate related assets; and manages and sells real estate properties acquired through foreclosure. The company was founded in 1839 and is headquartered in Jersey City, New Jersey.
Earnings Per Share
As for profitability, Provident Financial Services has a trailing twelve months EPS of $2.31.
PE Ratio
Provident Financial Services has a trailing twelve months price to earnings ratio of 7.33. Meaning, the purchaser of the share is investing $7.33 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.22%.
Yearly Top and Bottom Value
Provident Financial Services’s stock is valued at $16.94 at 14:23 EST, way below its 52-week high of $24.70 and way higher than its 52-week low of $14.54.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 32.8% and a negative 22.7%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth declined by 7.9%, now sitting on 491.04M for the twelve trailing months.
Sales Growth
Provident Financial Services’s sales growth is 14.7% for the current quarter and 40.1% for the next.
6. ENI S.p.A. (E)
33.22% Payout Ratio
Nordic Aqua Partners A/S, a land-based Atlantic salmon farming company, invests in, installs, and operates breeding systems for fish and shellfish in the People's Republic of China. The company was incorporated in 2016 and is based in Ribe, Denmark. Nordic Aqua Partners A/S operates as a subsidiary of Nordic Aqua A/S.
Earnings Per Share
As for profitability, ENI S.p.A. has a trailing twelve months EPS of $8.18.
PE Ratio
ENI S.p.A. has a trailing twelve months price to earnings ratio of 3.76. Meaning, the purchaser of the share is investing $3.76 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -14.49%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
ENI S.p.A.’s EBITDA is 0.56.
Volume
Today’s last reported volume for ENI S.p.A. is 73510 which is 67.57% below its average volume of 226706.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of $1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing $1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jan 1, 1970, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 1%.
Volume
Today’s last reported volume for 1 is 1 which is 1% above its average volume of 1.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 1% and 1%, respectively.
